Expert Review of Vaccines最新文献_第2页

Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE? 欧洲消除宫颈癌和预防人乳头瘤病毒（hpv）相关癌症的准备情况评估——我们是否赢得了竞赛？

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-15 DOI: 10.1080/14760584.2024.2438759

Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby

{"title":"Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE?","authors":"Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby","doi":"10.1080/14760584.2024.2438759","DOIUrl":"10.1080/14760584.2024.2438759","url":null,"abstract":"Introduction: To address the cervical cancer burden globally, the World Health Organization and European Union released strategies to facilitate HPV-related cancers prevention, including cervical cancer elimination. This research assessed European country level readiness to achieve cervical cancer elimination by adhering to such strategies.Areas covered: Readiness for cervical cancer elimination was assessed across a range of guiding questions relevant to three defined key domains: vaccination, screening, and treatment, each with two sub-domains focusing on decision making and implementation efforts. Publicly available data sources were used to inform the scoring across domains, to tier countries into either high, moderate-high, moderate-low, and low readiness archetypes.Key parameters identified associated with the high readiness archetype were high vaccination coverage rates (>70%), availability of gender neutral and catch-up vaccination, school-based vaccination availability, organized screening programs, use of HPV DNA primary screening tests, and data surveillance.Expert opinion: Our analysis highlights significant variability in decision making and implementation of vaccination, screening, and treatment programmes across Europe. Country scores expose the need for a multifaceted approach to achieve cervical cancer elimination in Europe, encompassing solid decision making commitments, implementation of these commitments, and the ability to collect, surveil, and apply the data use accurately.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"11-26"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response. 迈向丙型肝炎疫苗：引发有效b细胞反应的免疫策略概述。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-28 DOI: 10.1080/14760584.2025.2452955

Gabriel L Costa, Giuseppe A Sautto

{"title":"Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response.","authors":"Gabriel L Costa, Giuseppe A Sautto","doi":"10.1080/14760584.2025.2452955","DOIUrl":"10.1080/14760584.2025.2452955","url":null,"abstract":"Introduction: Fifty-eight million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antivirals are highly effective; however, they are burdened by high costs and the unchanged risk of HCC and reinfection, making prophylactic countermeasures an urgent medical need. HCV high genetic diversity is one of the main obstacles to vaccine development. The protective role of the humoral response directed against the HCV E2 glycoprotein is well established, and broadly neutralizing antibodies play a crucial role in effective viral clearance.Areas covered: This review explores the HCV targets and the different vaccination approaches, encompassing different expression systems, antigen selection strategies, and delivery methods, focusing on those aimed at eliciting a broad and effective humoral response. Our search criteria included the keywords 'HCV,' 'Hepatitis C,' and 'vaccine' using publicly available databases. Following the screening, 54 papers were selected.Expert opinion: The investigation of novel vaccine platforms beyond traditional approaches is necessary. While progress has been made in this direction, continued investigations on the HCV virology, immunology, and vaccinology are essential to surmount associated obstacles, heling in the development of an HCV vaccine that can benefit the global public health.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"96-120"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants. 二价蛋白COVID-19疫苗SCTV01C对抗原匹配和不匹配变体的持续免疫原性

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/14760584.2025.2456231

Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie

{"title":"Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.","authors":"Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie","doi":"10.1080/14760584.2025.2456231","DOIUrl":"10.1080/14760584.2025.2456231","url":null,"abstract":"Background: The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.Research design and methods: In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primary series of two doses and a booster dose of SCTV01C, a bivalent protein SARS-CoV-2 vaccine.Results: Geometric mean titers (GMTs) of neutralizing antibodies (nAb) against live Alpha, Beta, Delta, and Omicron showed 85.4-, 100.0-, 32.1-, and 9.8-fold increase from baseline on 28 days, and 49.4-, 55.3-, 5.7-fold increase against live Alpha, Beta, and Omicron on 90 days after primary series. At Day 28 and Day 90 following the booster dose, GMTs of nAb against Beta, BA.2 and BA.5 variants showed 12.1- and 8.8-, 13.8- and 7.1-, 18.7-, and 11.9-fold of increase from baseline, respectively. Reactogenicity was generally mild, with one adverse event of special interest (AESI) and 9 ≥Grade 3 treatment-related adverse events (TRAEs); all recovered within 3 days.Conclusions: SCTV01C, when administered as both a primary series and a booster vaccination, exhibited encouraging sustained immunogenicity against both antigen-matched and antigen-mismatched variants, with no significant safety concerns.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05148091.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"128-137"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States. 美国成年人对肺炎球菌疫苗的了解、态度和看法。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-19 DOI: 10.1080/14760584.2024.2441250

Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier

{"title":"Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.","authors":"Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier","doi":"10.1080/14760584.2024.2441250","DOIUrl":"10.1080/14760584.2024.2441250","url":null,"abstract":"Objectives: The attitudes and perceptions of healthcare consumers (HCCs) are increasingly becoming more relevant in decision-making with healthcare providers and incorporated into healthcare decision-making by national immunization technical advisory groups and health technology assessment agencies. With newer pneumococcal vaccine options available, HCCs' attitudes and perceptions play a key role in gauging potential acceptance. The objective of this study was to assess HCCs' knowledge, attitudes, and perceptions toward pneumococcal vaccines for adults.Methods: Between March and May 2024, eligible U.S. adult HCCs were invited to participate in an online survey focusing on experiences and attitudes toward vaccines.Results: Among 141 participating HCCs, average age was 53.1 years. The majority of participants were male (51.1%) and 64.5% identified as White. Most HCCs received at least one vaccine in the past year (81.6%). HCCs most often received vaccines at medical offices and pharmacies. HCCs supported lowering the age-based pneumococcal vaccine recommendation to all adults 50 years and older and were willing to receive a supplemental pneumococcal vaccine dose following completion of the recommended series for additional protection.Conclusions: These findings indicate that new adult pneumococcal vaccines would be accepted and valued by HCCs if recommended by HCPs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"45-52"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia. 利用沙特阿拉伯王国的适应疫苗对不同COVID-19疫苗接种策略的潜在公共卫生和经济影响进行建模。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-17 DOI: 10.1080/14760584.2024.2438757

Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff

{"title":"Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia.","authors":"Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff","doi":"10.1080/14760584.2024.2438757","DOIUrl":"10.1080/14760584.2024.2438757","url":null,"abstract":"Background: The dynamic evolution of the virus causing COVID-19 necessitates the development of adapted vaccines to protect against emerging variants.Research design and methods: A combined Markov-decision tree model estimated the outcomes of alternative vaccination strategies. The Saudi Arabian population was stratified into standard-risk and high-risk subpopulations, defined as either the population comprising individuals aged ≥ 65 years and individuals with at least one comorbidity. The model estimated the health and economic outcomes of vaccination based on age-specific inputs taken from published sources and national surveillance data.Results: The vaccination strategy targeting the elderly and high-risk subpopulation (was estimated to prevent 156,694 cases 12,800 hospitalizations, and 2,919 deaths and result in cost savings of SAR 1,239 million in direct costs and SAR 4,145 million in indirect costs. These gains increased with the vaccination strategies additionally targeting other subpopulations. Compared to the base case (aged ≥65 and those at high-risk), expanding vaccination coverage to 75% of the standard-risk population prevented more cases (323%), hospitalizations (154%), and deaths (60%) and increased the direct (232%) and indirect (270%) cost savings.Conclusions: The adoption of broad vaccination strategies using a vaccine adapted to the dominant variant in circulation would yield substantial benefits in Saudi Arabia.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"27-36"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials. 不同技术平台上5种COVID-19疫苗的不良反应特征：9项临床试验的汇总分析

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-07 DOI: 10.1080/14760584.2025.2502031

Yue Liu, Qian Liu, Lai-Run Jin, Wei-Wei Han, Ming-Wei Wei, Si-Yue Jia, Feng-Cai Zhu, Jing-Xin Li

{"title":"Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials.","authors":"Yue Liu, Qian Liu, Lai-Run Jin, Wei-Wei Han, Ming-Wei Wei, Si-Yue Jia, Feng-Cai Zhu, Jing-Xin Li","doi":"10.1080/14760584.2025.2502031","DOIUrl":"https://doi.org/10.1080/14760584.2025.2502031","url":null,"abstract":"Background: Evidence regarding the comparative safety of different COVID-19 vaccines remains limited. This study aims to characterize and compare the safety profiles of five COVID-19 vaccines in terms of adverse reactions after immunization.Research design and methods: We conducted a retrospective analysis of adverse reactions reported among adults aged 18-59 years from nine clinical trials. The analyzed vaccines included inactivated, recombinant protein, intranasal influenza-vectored, aerosolized and intramuscular Ad5 vectored COVID-19 vaccines. Factor analysis and association rule analysis were used to characterize adverse reaction patterns, while multivariate logistic regression was employed to assess the influence of vaccine type and demographic factors.Results: Inactivated, recombinant, and intramuscular Ad5 vectored vaccines commonly caused injection site pain, fatigue, headache, and pyrexia from the SOC of 'General disorders and administration site conditions.' Intranasal influenza-vectored vaccines mainly cause respiratory symptoms such as rhinorrhea and nasal congestion, while dry mouth and oropharyngeal pain from 'Gastrointestinal disorders' were primarily observed in aerosolized Ad5 vectored vaccines. Younger age (p < 0.001), female sex (p = 0.001), comorbidities (p < 0.001), and intramuscular Ad5 vectored vaccines (p < 0.001) were significantly associated with higher adverse reaction risks.Conclusions: COVID-19 vaccines developed through different technological approaches have distinct adverse reaction profiles.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"339-349"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China. 一种减毒水痘活疫苗在13 - 55岁健康受试者中的免疫原性和安全性：一项在中国开展的双盲、随机、主动对照iii期临床试验

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-02-07 DOI: 10.1080/14760584.2025.2457463

Yang Zhang, Shiyuan Wang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Hongxing Pan, Jinfang Sun

{"title":"Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China.","authors":"Yang Zhang, Shiyuan Wang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Hongxing Pan, Jinfang Sun","doi":"10.1080/14760584.2025.2457463","DOIUrl":"10.1080/14760584.2025.2457463","url":null,"abstract":"Background: Adolescents and adults who contract chickenpox are at a higher risk of severe complications. Vaccination with the varicella vaccine (VarV) effectively prevents chickenpox.Research design and methods: In this phase III, single-center, randomized, double-blind, active-controlled trial, 1,200 healthy participants were randomly assigned in a 1:1 ratio to receive two doses of either the test vaccine or the active control vaccine. Varicella-zoster virus (VZV) antibody was detected before vaccination and 42 days after the two doses of vaccination.Results: The lower limits of the 95% CI for the differences in seroconversion rates and geometric mean titer (GMT) ratios between the two groups were greater than their respective pre-set non-inferiority margins. The overall incidence of Adverse events (AEs) and adverse reactions (ARs) in the test group was significantly lower than those in the control group. Additionally, the incidence rates of swelling and fatigue were lower in the test group compared to the control group after vaccination.Conclusions: The test freeze-dried live attenuated VarV demonstrated good immunogenicity and higher safety compared to the active control vaccine in healthy participants aged 13-55 years.Clinical trials registration: www.clinicaltrials.gov identifier: NCT06592456.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"157-164"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Virus-like particles: a versatile and effective vaccine platform. 病毒样颗粒：一个多功能和有效的疫苗平台。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-22 DOI: 10.1080/14760584.2025.2508517

Martin F Bachmann, Pierre van Damme, Florian Lienert, Tino F Schwarz

{"title":"Virus-like particles: a versatile and effective vaccine platform.","authors":"Martin F Bachmann, Pierre van Damme, Florian Lienert, Tino F Schwarz","doi":"10.1080/14760584.2025.2508517","DOIUrl":"10.1080/14760584.2025.2508517","url":null,"abstract":"Introduction: Traditional live-attenuated or inactivated vaccines have limitations, including risks associated with uncontrolled replication, reduced immunogenicity, or production complexities. To address these issues, alternative platforms such as virus-like particles (VLPs) have been developed.Areas covered: VLPs are self-assembling structures composed of viral proteins that mimic native viruses but are noninfectious. This review provides an overview of their structure, design and manufacture that make them an attractive platform for vaccine development. We then discuss the clinical development of some recently approved VLP vaccines and those widely used in immunization programs, summarizing the clinical trial data that underpins their efficacy and safety profiles. Additionally, we explore VLP vaccines in late-stage clinical development for respiratory syncytial virus and human metapneumovirus.Expert opinion: VLPs are a versatile and promising platform for vaccine development. Their ability to mimic native viruses while eliminating the risks associated with live vaccines positions them as an attractive platform for vaccine design. Currently approved VLP vaccines demonstrate that they can provide effective protection against a wide range of diseases. Advances in VLP design and production are likely to lead to highly effective vaccines, significantly contributing to global immunization efforts.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"444-456"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States. 评估美国成人疫苗接种覆盖率的非调查数据来源的优势和局限性。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-27 DOI: 10.1080/14760584.2025.2483719

Matthew F Daley, Kamonthip J Homdayjanakul, Laura P Hurley, Peng-Jun Lu, Yuping Tsai, Carla L Black, Suchita Patel, James A Singleton, Lori A Crane

{"title":"Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States.","authors":"Matthew F Daley, Kamonthip J Homdayjanakul, Laura P Hurley, Peng-Jun Lu, Yuping Tsai, Carla L Black, Suchita Patel, James A Singleton, Lori A Crane","doi":"10.1080/14760584.2025.2483719","DOIUrl":"10.1080/14760584.2025.2483719","url":null,"abstract":"Introduction: Non-survey-based data sources (e.g. electronic health records, administrative claims) have been used to estimate vaccination coverage among US adults. However, these data sources were not collected for research or surveillance purposes and may have substantial limitations. The objectives of this narrative review were to: 1) identify published studies that used non-survey-based data sources to estimate adult vaccination coverage for one or more routinely recommended vaccines; and 2) summarize the strengths and limitations of these data sources for coverage assessments.Areas covered: Thirty-four publications derived from 9 data sources were reviewed: 16 publications were in a general population (i.e. defined by age), 12 were among pregnant women, and 6 were among individuals with chronic health conditions. While several data sources used continuous health insurance enrollment to define the study population, doing so limited generalizability to stably insured populations. Methods for obtaining race and ethnicity data were complex and potentially subject to bias. None of the reviewed studies presented any formal assessment of vaccine data validity.Expert opinion: While multiple non-survey-based data sources have been used to assess adult vaccination coverage in the United States, important limitations exist, including related to generalizability, data validity, and risk of bias.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"230-241"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis. omicron XBB 1.5适应COVID-19疫苗的比较有效性：系统文献综述和网络荟萃分析

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-19 DOI: 10.1080/14760584.2025.2505754

Kyle Fahrbach, Allie Cichewicz, Haitao Chu, Manuela Di Fusco, Heather Burnett, Hannah R Volkman, Morodoluwa Akin-Fajiye, Carlos Fernando Mendoza, Joseph C Cappelleri

{"title":"Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.","authors":"Kyle Fahrbach, Allie Cichewicz, Haitao Chu, Manuela Di Fusco, Heather Burnett, Hannah R Volkman, Morodoluwa Akin-Fajiye, Carlos Fernando Mendoza, Joseph C Cappelleri","doi":"10.1080/14760584.2025.2505754","DOIUrl":"10.1080/14760584.2025.2505754","url":null,"abstract":"Introduction: Comparative effectiveness data of COVID-19 vaccines remain limited. We conducted a systematic review and network meta-analysis (NMA) feasibility assessment of effectiveness studies of Omicron-adapted COVID-19 vaccines.Research design and methods: Searches in MEDLINE and Embase up to February 2025 identified studies comparing the effectiveness of Omicron-adapted COVID-19 vaccines, either directly or against no recent vaccine. Two investigators independently selected articles reporting adjusted vaccine effectiveness (VE). A feasibility assessment determined the appropriateness of a common comparator and evaluated effect modifiers (EMs). Data extraction and risk-of-bias assessment were performed by one investigator and validated by a second investigator. Bayesian NMAs using random-effects models were performed for base-case analyses, data permitting.Results: The review identified 25 studies for Omicron-adapted COVID-19 vaccines: 16 for XBB formulations, eight of which were included in NMAs, all for mRNA formulations, representing 29.9 million participants. BNT162b2 had the largest evidence base. Comparisons between XBB.1.5-adapted BNT162b2 (Comirnaty) and mRNA-1273 (Spikevax) found that both vaccines are effective and comparable against XBB-related hospitalizations, infections, and medically attended visits in adults Among elderly, the estimated effectiveness against XBB-related hospitalizations favored BNT162b2.Conclusions: Findings of this NMA of observational studies support the effectiveness of XBB.1.5-adapted mRNA vaccines. Limitations included assumptions on EMs and sparse evidence networks.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"416-432"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0